8-KOther EventsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Feb 29, 2008)

Filed February 29, 2008For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced a significant milestone in its Form 8-K filing dated February 28, 2008, reporting that on February 27, 2008, the company received marketing approval from the U.S. Food and Drug Administration (FDA) for ARCALYST™ (rilonacept) Injection for Subcutaneous Use. This approval marks the first indication for ARCALYST, positioning it as a treatment for Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in patients aged 12 and older. This FDA approval is a crucial development for Regeneron, signifying the successful transition of a key pipeline asset to commercialization. Investors should view this as a validation of the company's research and development efforts and a potential driver of future revenue growth. The approval for ARCALYST addresses a significant unmet need in rare autoinflammatory diseases, potentially establishing Regeneron as a leader in this therapeutic area.

Key Highlights

  • 1FDA marketing approval granted for ARCALYST™ (rilonacept) Injection for Subcutaneous Use.
  • 2ARCALYST is approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).
  • 3Target patient population includes adults and children aged 12 and older with FCAS and MWS.
  • 4This approval represents a significant commercialization milestone for Regeneron.
  • 5The drug is an interleukin-1 blocker, targeting specific inflammatory pathways.
  • 6This event was officially announced via a press release on February 27, 2008.

Frequently Asked Questions

ARCALYST (rilonacept) Injection for Subcutaneous Use is an interleukin-1 blocker approved by the FDA for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), specifically Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 years of age and older.

This FDA approval is a major event for Regeneron as it represents the first marketing approval for ARCALYST, moving a key drug candidate from development to commercialization. It validates the company's R&D capabilities and opens a new revenue stream.

An interleukin-1 blocker, like ARCALYST, works by inhibiting the activity of interleukin-1, a protein that plays a key role in causing inflammation in the body. By blocking this protein, ARCALYST helps to reduce the symptoms associated with inflammatory conditions like CAPS.

Regeneron Pharmaceuticals, Inc. issued a press release announcing the FDA approval on February 27, 2008, which was subsequently filed in this Form 8-K report.